Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy.
Journal of thrombosis and haemostasis : JTH 2013 Aug 11 (8): 1617-9.
Blondon M, Wiggins K L, Harrington L B, Psaty B M, Smith N
Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.
Clinical pharmacology and therapeutics 2011 Jan 89 (1): 60-4.
Bouligand J, Cabaret O, Canonico M, Verstuyft C, Dubert L, Becquemont L, Guiochon-Mantel A, Scarabin P Y,